Resident Blog - Edith Ford episode artwork

EPISODE · Nov 26, 2024 · 20 MIN

Resident Blog - Edith Ford

from The mTOR You Know · host The mTOR You Know

PGY2 SOT Edith Ford joins us from Mayo Clinic in Phoenix, Arizona to discuss "A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection", which has recently received Breakthrough Therapy Designation for ABMR in kidney transplant recipients, as well as a quick discussion on antibody-mediated rejection and CD38 inhibitors.

PGY2 SOT Edith Ford joins us from Mayo Clinic in Phoenix, Arizona to discuss "A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection", which has recently received Breakthrough Therapy Designation for ABMR in kidney transplant recipients, as well as a quick discussion on antibody-mediated rejection and CD38 inhibitors.

NOW PLAYING

Resident Blog - Edith Ford

0:00 20:57

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Frequently Asked Questions

How long is this episode of The mTOR You Know?

This episode is 20 minutes long.

When was this The mTOR You Know episode published?

This episode was published on November 26, 2024.

What is this episode about?

PGY2 SOT Edith Ford joins us from Mayo Clinic in Phoenix, Arizona to discuss "A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection", which has recently received Breakthrough Therapy Designation for ABMR in kidney transplant...

Can I download this The mTOR You Know episode?

Yes, you can download this episode by clicking the download button on the episode player, or subscribe to the podcast in your preferred podcast app for automatic downloads.
URL copied to clipboard!